RT Journal Article
SR Electronic
T1 Digestive Manifestations in Patients Hospitalized with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.07.20143024
DO 10.1101/2020.07.07.20143024
A1 Elmunzer, B. Joseph
A1 Spitzer, Rebecca L.
A1 Foster, Lydia D.
A1 Merchant, Ambreen A.
A1 Howard, Eric F.
A1 Patel, Vaishali A.
A1 West, Mary K.
A1 Qayed, Emad
A1 Nustas, Rosemary
A1 Zakaria, Ali
A1 Piper, Marc S.
A1 Taylor, Jason R.
A1 Jaza, Lujain
A1 Forbes, Nauzer
A1 Chau, Millie
A1 Lara, Luis F.
A1 Papachristou, Georgios I.
A1 Volk, Michael L.
A1 Hilson, Liam G.
A1 Zhou, Selena
A1 Kushnir, Vladimir M.
A1 Lenyo, Alexandria M.
A1 McLeod, Caroline G.
A1 Amin, Sunil
A1 Kuftinec, Gabriela N.
A1 Yadav, Dhiraj
A1 Fox, Charlie
A1 Kolb, Jennifer M.
A1 Pawa, Swati
A1 Pawa, Rishi
A1 Canakis, Andrew
A1 Huang, Christopher
A1 Jamil, Laith H.
A1 Aneese, Andrew M.
A1 Glamour, Benita K.
A1 Smith, Zachary L
A1 Hanley, Katherine A.
A1 Wood, Jordan
A1 Patel, Harsh K.
A1 Shah, Janak N.
A1 Agarunov, Emil
A1 Sethi, Amrita
A1 Fogel, Evan L.
A1 McNulty, Gail
A1 Haseeb, Abdul
A1 Trieu, Judy A.
A1 Dixon, Rebekah E.
A1 Yang, Jeong Yun
A1 Mendelsohn, Robin B.
A1 Calo, Delia
A1 Aroniadis, Olga C.
A1 LaComb, Joseph F.
A1 Scheiman, James M.
A1 Sauer, Bryan G.
A1 Dang, Duyen T.
A1 Piraka, Cyrus R.
A1 Shah, Eric D.
A1 Pohl, Heiko
A1 Tierney, William M.
A1 Mitchell, Stephanie
A1 Condon, Ashwinee
A1 Lenhart, Adrienne
A1 Dua, Kulwinder S.
A1 Kanagala, Vikram S.
A1 Kamal, Ayesha
A1 Singh, Vikesh K.
A1 Pinto-Sanchez, Maria Ines
A1 Hutchinson, Joy M.
A1 Kwon, Richard S.
A1 Korsnes, Sheryl J.
A1 Singh, Harminder
A1 Solati, Zahra
A1 Deshpande, Amar R.
A1 Rockey, Don C.
A1 Alford, Teldon B.
A1 Durkalski, Valerie
A1 the North American Alliance for the Study of Digestive Manifestations of COVID-19.
YR 2020
UL http://medrxiv.org/content/early/2020/08/11/2020.07.07.20143024.abstract
AB Background The prevalence and significance of digestive manifestations in COVID-19 remain uncertain.Methods Consecutive patients hospitalized with COVID-19 were identified across a geographically diverse alliance of medical centers in North America. Data pertaining to baseline characteristics, symptomatology, laboratory assessment, imaging, and endoscopic findings from the time of symptom onset until discharge or death were manually abstracted from electronic health records to characterize the prevalence, spectrum, and severity of digestive manifestations. Regression analyses were performed to evaluate the association between digestive manifestations and severe outcomes related to COVID-19.Results A total of 1992 patients across 36 centers met eligibility criteria and were included. Overall, 53% of patients experienced at least one gastrointestinal symptom at any time during their illness, most commonly diarrhea (34%), nausea (27%), vomiting (16%), and abdominal pain (11%). In 74% of cases, gastrointestinal symptoms were judged to be mild. In total, 35% of patients developed an abnormal alanine aminotransferase or total bilirubin level; these were elevated to less than 5 times the upper limit of normal in 77% of cases. After adjusting for potential confounders, the presence of gastrointestinal symptoms at any time (odds ratio 0.93, 95% confidence interval 0.76-1.15) or liver test abnormalities on admission (odds ratio 1.31, 95% confidence interval 0.80-2.12) were not independently associated with mechanical ventilation or death.Conclusions Among patients hospitalized with COVID-19, gastrointestinal symptoms and liver test abnormalities were common but the majority were mild and their presence was not associated with a more severe clinical courseCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialThis was an observational studyFunding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional review board approval was obtained at each center prior to patient identification and data collection.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll authors had access the data